Investor Relations Activity Record Form
Filed with SSE · · 4 pages · Chinese
Jiangsu Lianhuan Pharmaceutical Co., Ltd. on 6ix
Earlier from Jiangsu Lianhuan Pharmaceutical
- Announcement on the Company's Receipt of the Approval for Marketing of a Chemical API
- Announcement on Execution of the "Project Entry Agreement" by the Company and Its Controlled Subsidiary and the Progress of External Investment
- Announcement on Acquisition of Drug Registration Certificate by a Controlled Subsidiary
- Semi-annual Performance Forecast for 2026
- Announcement on Abnormal Fluctuations in Stock Trading
Later from Jiangsu Lianhuan Pharmaceutical
- Announcement on the Proposed Selection of the Company and Controlled Subsidiary in the 12th Batch of National Centralized Drug Procurement
- Announcement on Obtaining Drug Registration Certificate
- Announcement on Resolutions of the 26th Extraordinary Meeting of the 9th Board of Directors
- Announcement on the Addition of a Related Party Not Under Common Control and Increase of the Estimated Amount of Routine Related Party Transactions for 2026
- Semi-annual Report for 2026
Follow Jiangsu Lianhuan Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Lianhuan Pharmaceutical